US Federal 2023-2024 Regular Session

US Federal Senate Bill SB775

Introduced
3/14/23  

Caption

Increasing Transparency in Generic Drug Applications Act

Impact

This legislation is expected to strengthen regulatory oversight by ensuring that generic drugs meet the same standards as their branded counterparts, which could affect both manufacturers and consumers. By increasing the transparency of the application process, the bill seeks to foster greater confidence in generic medications, potentially boosting their utilization. Additionally, this could lead to more stringent quality controls within the pharmaceutical industry regarding active and inactive ingredients.

Summary

SB775, known as the Increasing Transparency in Generic Drug Applications Act, aims to enhance the transparency of the generic drug approval process. The bill mandates that the Secretary of Health and Human Services (HHS) provide clear disclosures regarding the equivalence of generic drugs to their branded counterparts. Specifically, when a request for an abbreviated application is made, the Secretary will determine whether the drug in question contains the same inactive ingredients and disclose any deviations discovered during the evaluation process, including quantitative discrepancies.

Contention

Notable points of contention surrounding SB775 include the balance between ensuring drug safety and maintaining the efficiency of the drug approval process. Critics may raise concerns about the potential bureaucratic burden on the FDA due to additional disclosure requirements, which could prolong the time taken to approve new generics. Conversely, advocates assert that the measure is necessary for public health, ensuring that generic drugs are both safe and effective for consumer use, thereby promoting competition and lowering drug costs.

Companion Bills

US SB1114

Related Expanding Access to Low-Cost Generics Act of 2023

US HB3561

Related PATIENT Act of 2023 Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023

US HB3839

Related To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

US HB5378

Related Lower Costs, More Transparency Act

Previously Filed As

US SB1302

Increasing Transparency in Generic Drug Applications Act

US HB1843

To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.

US SB477

relative to increasing transparency in the 340B Drug Pricing Program.

US HB1168

Increasing transparency in artificial intelligence.

US S2122

Relative to increasing transparency in public construction

US HB1277

Increasing Transparency Impact of Fuel Products

US HB1906

AN ACT Relating to increasing transparency and consumer protection in water system rates;

US S1035

Relative to increasing transparency in juvenile court proceedings

US H3356

Relative to transparency for grant applications

US SB229

DTC Act of 2025 Drug-price Transparency for Consumers Act of 2025

Similar Bills

CA SB493

An act to amend Section 4508 of the Food and Agricultural Code, relating to fairs.

LA HB1037

Modifies operations and certain positions within the Department of Transportation and Development (EN NO IMPACT See Note)

LA HB528

Reforms the organizational structure for the Department of Transportation and Development including its duties, powers, and responsibilities of officers and employees (EN INCREASE SD EX See Note)

US HB2482

NTIA Reauthorization Act of 2025 National Telecommunications and Information Administration Reauthorization Act of 2025

AR SB63

To Amend Arkansas Law Concerning Reports By The Secretaries Of Cabinet-level Departments On The State Of Their Departments.

CA AB655

An act to amend Section 99522 of the Government Code, relating to state government.

IA HSB665

A bill for an act providing for certain business entities acting under the jurisdiction of the secretary of state by providing for the removal of information from a filing based on a sworn affidavit and administrative dissolution based on the response to interrogatories.(See HF 2678.)